Athymic nu/nu (Nude) mice are resistant to CD45RBhigh T-cell-mediated chronic colitis: Role of NK cells

2001 ◽  
Vol 120 (5) ◽  
pp. A38-A38
Author(s):  
F LAROUX ◽  
L GRAY ◽  
S BHARWANI ◽  
D MERRILL ◽  
J FUSELER ◽  
...  
Keyword(s):  
T Cell ◽  
Nk Cells ◽  
2001 ◽  
Vol 120 (5) ◽  
pp. A38
Author(s):  
F. Stephen Laroux ◽  
Laura Gray ◽  
Sulaiman Bharwani ◽  
Dana Merrill ◽  
John Fuseler ◽  
...  
Keyword(s):  
T Cell ◽  
Nk Cells ◽  

2003 ◽  
Vol 124 (4) ◽  
pp. A486
Author(s):  
Stephen Laroux ◽  
Laura Gray ◽  
Sulaiman Bharwani ◽  
Dana Merrill ◽  
John Fuseler ◽  
...  
Keyword(s):  
T Cell ◽  
B Cells ◽  

2015 ◽  
pp. 353-356 ◽  
Author(s):  
Kazuo Shimanura ◽  
Koji Maruo ◽  
Yoshito Ueyama ◽  
Sonoko Habu ◽  
Ko Okumura ◽  
...  

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 398-398 ◽  
Author(s):  
Frederic Baron ◽  
T. Gooley ◽  
M.T. Little ◽  
E. Petersdorf ◽  
M. Malkki ◽  
...  

Abstract Purpose and methods: The clinical significance of donor NK cell engraftment after nonmyeloablative conditioning for allogeneic HCT is not defined. We prospectively investigated the relationship between kinetics of donor engraftment of T-cells and NK cells and outcomes in 229 pts (130 with HLA-matched related donors and 99 with unrelated donors) conditioned with 2 Gy TBI +/− fludarabine. Diagnoses were hematological malignancies (n=217), solid tumors (n=8), or primary immunodeficiency diseases (n=4). T-cells (CD3+CD56−) and NK cells (CD3−CD14−CD56+) were isolated from PB by flow cytometry on days 14, 28 and 42 after HCT. The proportions of cells of donor and host origin were assessed by VNTR-PCR and quantification with phosphorimaging. Results: Median T-cell and NK cell chimerism levels were 66 (range, 1–100)% and 78 (range, 3–100)% on day 14, 77 (range, 1–100)% and 88 (range, 2–100)% on day 28, and 81 (range, 1–100)% and 88 (range, 1–100)% on day 42, respectively. The Spearman correlation coefficient between day-14 T-cell and NK cell chimerism levels was 0.59. Day-14 T-cell (P=.0005) and NK cell (P=.0003) chimerism levels < 50% were each associated with increased risks of graft rejection. Modeling chimerism levels as a continuous linear variable, high T-cell (P=.01) but not NK cell (P=.21) chimerism levels on day 14 were associated with increased probability of acute GVHD. Further, both high levels of T-cell (P=.008) and NK cell (P=.005) donor chimerism levels on days 14–42 were associated with decreased risk of relapse in time-dependent analyses adjusted for disease risk, while high levels of donor NK cell (but not T-cell) chimerism were associated with better overall (OS; P=.003) and progression-free (PFS; P=.003) survivals when adjusting for disease risk (Table 1). To further characterize the role of NK cells on relapse, we investigated the impact of missing donor KIR ligand on HCT outcome in 150 of the 229 pts (Blood2005, vol 150, p4878). Although no statistically significant association between missing any donor KIR ligand(s) and PFS was seen, there was a suggestion for a lower risk of relapse in patients missing 1-donor KIR ligand (HR=0.61, p=.15). Conclusions: High levels of donor T-cell chimerism were associated with a lower risk of relapse, a benefit which was offset by higher incidence of acute GVHD leading to a trend for increased nonrelapse mortality. Conversely, earlier establishment of donor NK-cell chimerism was associated with a lower risk of relapse without increasing acute GVHD, leading to improved OS. Further studies are needed to define the role of NK alloreactivity after nonmyeloablative conditioning. Association between donor T-cell and NK cell chimerism levels and HCT outcomes (p values). T-cell NK cell Chimerism levels were modeled as a continuous linear variable. Grade II–IV acute GVHD p=.01 (higher risk with increasing chimerism level) p=.21 (higher risk with increasing chimerism level) Relapse p=.008 (lower risk with increasing chimerism level) p=.005 (lower risk with increasing chimerism level) Nonrelapse mortality p=.13 (higher risk with increasing chimerism level) p=.26 (lower risk with increasing chimerism level) PFS p=.16 (better PFS with increasing chimerism level) p=.003 (better PFS with increasing chimerism level) OS p=.77 (better OS with increasing chimerism level) p=.003 (better OS with increasing chimerism level)


Blood ◽  
2011 ◽  
Vol 118 (18) ◽  
pp. 4919-4929 ◽  
Author(s):  
Siok-Bian Ng ◽  
Junli Yan ◽  
Gaofeng Huang ◽  
Viknesvaran Selvarajan ◽  
Jim Liang-Seah Tay ◽  
...  

Abstract We performed a comprehensive genome-wide miRNA expression profiling of extranodal nasal-type natural killer/T-cell lymphoma (NKTL) using formalin-fixed paraffin-embedded tissue (n = 30) and NK cell lines (n = 6) compared with normal NK cells, with the objective of understanding the pathogenetic role of miRNA deregulation in NKTL. Compared with normal NK cells, differentially expressed miRNAs in NKTL are predominantly down-regulated. Re-expression of down-regulated miRNAs, such as miR-101, miR-26a, miR26b, miR-28-5, and miR-363, reduced the growth of the NK cell line and modulated the expression of their predicted target genes, suggesting the potential functional role of the deregulated miRNAs in the oncogenesis of NKTL. Taken together, the predicted targets whose expression is inversely correlated with the expression of deregulated miRNA in NKTL are significantly enriched for genes involved in cell cycle-related, p53, and MAPK signaling pathways. We also performed immunohistochemical validation for selected target proteins and found overexpression of MUM1, BLIMP1, and STMN1 in NKTL, and notably, a corresponding increase in MYC expression. Because MYC is known to cause repression of miRNA expression, it is possible that MYC activation in NKTL may contribute to the suppression of the miRNAs regulating MUM1, BLIMP1, and STMN1.


2014 ◽  
Vol 275 (1-2) ◽  
pp. 54-55
Author(s):  
Eric Armentani ◽  
Alice Laroni ◽  
Federico Ivaldi ◽  
Roopali Gandhi ◽  
Ilaria Gandoglia ◽  
...  

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A15-A16
Author(s):  
Ravindra Kumar Shukla ◽  
Ramkaran Choudhary ◽  
Mahendra Lodha ◽  
Mahaveer singh Rodha ◽  
Nitin Bajpai ◽  
...  

Abstract Introduction: Role of T cells in VAT inflammation is poorly characterised. Perforin deficiency is associated with autoimmune inflammatory diseases like Hemophagocytosis Lymphohistiocytosis,as also in context of type 1 DM pathogenesis. Data from animal models suggest that perforin deficiency leads to VAT inflammation1Objective: We hypothesized CD8+/perf+ and CD56+/perf+ cells to be decreased in type 2 DM as compared to healthy controls. The present study also explored the difference in activation of T/NK cells between two groups Methods: 2×2 cm omental tissue was obtained from subjects undergoing elective abdominal surgery. The sample was transported in RPMI solution and stored in -80 ℃. Processing involved thawing, incubation at 37.6 ℃ for 24 hours with type IV Collagenase (1 mg/ml, Sigma Aldrich) 1ml/g of tissue,centrifuge (32g for 10 min at 10℃). The resultant Stromal Vascular fraction (SVF) was suspended in phosphate buffer saline (PBS), passed through cell strainer to make single cell suspension. It was again centrifuged and tagged with CD markers of interest. Fc block was added and single cell solution with FACS fluid prepared. It was run in BD CANTO-2 flow cytometer as described2Results: Of seventeen samples analysed, twelve samples of type 2 diabetes subjects were compared with five healthy controls. All results are presented in median. The diabetics had higher HbA1c (8.1 % vs 6%), higher BMI (28 kg/m2 vs 24 kg/m2), hsCRP(2.1 mg/dl Vs 0.9 mg/dl) but there was no difference in HOMA-Ir (5 vs 5.2 mU/L/mg/dl). The percentage of CD4+ + CD8+ cells/g of VAT was similar in both cases and control (20 × 103 Vs 23× 103). CD8+/CD45+/perf+ and CD56+/CD45+/perf+ could not be identified in any of the samples. Although CD8+/CD45+/perf-- and CD56+/CD45+/perf-- cells were identified. Next, we analysed the same cells for cytotoxic activation by 107a. The percentage of 107a positivity was low in CD 8+ (7% and 4 % respectively in cases and control) and CD 56+ cells (10% and 9 % respectively in cases and control),Although clinically type 2 DM subjects were obese and had inflammation (i.e higher hsCRP), there was no difference in VAT activation of immune cells studied. Also, we could not delineate perforin in any of the samples. Conclusion: Taken together this work suggests VAT T cell immune milieu in human Type 2 DM is different from mouse model. It is neither characterised by perforin deficiency nor activation of T cell/NK cell. This study points towards the probability that, the role of T cell/NK cells in human VAT infiltration could be fundamentally different from mice models. Further studies should be focussed on functional characteristics of these cells and interaction with VAT macrophages. References 1. Xavier S. Revelo et al Diabetes 2015;64:90–103 2. Wetzels S et al J Vis Exp. 2018 Mar 6;(133):57319.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 4093-4093
Author(s):  
Tegan A Francis ◽  
Nicholas J Davies ◽  
Michael John Griffiths ◽  
Angelo Agathanggelou ◽  
Maha Ibrahim ◽  
...  

Abstract Inactivation of Ataxia Telangiectasia Mutated (ATM) gene, a principal regulator of DNA damage responses, is a frequent event in a wide range of sporadic B and T cell lymphoid malignancies and gives rise to ataxia telangiectasia (A-T) characterized by predisposition to a similar tumor spectrum. Due to the defect in ATM/p53 dependent apoptosis, tumors with Atmalterations exhibit poor responses to standard chemotherapy and require novel therapeutic approaches that need testing in preclinical models. Current animal models for ATM-deficient lymphoid malignancies are limited as they show bias for a single tumor type, mostly thymic lymphoma. We hypothesized that by crossing Atm-/- mice with athymic nude mice (nu-/-) that lack thymic development, the survival of animals would increase, permitting the development of ATM-deficient B cell lymphoid malignancies. As predicted, overall survival of Atm-/-nu-/- (median survival 21 months) mice greatly increased compared to Atm-/- animals that succumb to thymic lymphomas by 4 months (median survival 13 weeks; p<.0001). More importantly, the increased survival was coupled with a shift in the spectrum of malignancies with a predominance of B cell lymphomas. Altogether, neoplasms occurred in 24.3% (17 out of 70) of Atm-/-nu-/- mice revealing variable localization (spleen, liver, abdomen, thorax or axillary region) and immunochemistry consistent with diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt's lymphoma, CLL-like disease as well as T cell anaplastic large cell lymphoma (ALCL). Similar to A-T patients, DLBCL was the most frequent type of malignancy, observed in 58.8% (10 out of 17) of all cases. The phenotypic heterogeneity of B cell tumors was further supported through their differing cellular origin which encompassed both tumors with independent VDJ recombination as well as those with monoclonal VDJ recombination with or without VH somatic hypermutation. Thus, the development of Atm-/-nu-/-lymphomas was consistent with the role of the germinal centre together with remaining T cells in lymphomagenesis. Importantly, in three animals, lymphomas from different sites shared common VDJ recombination and lymphomas could be propagated into secondary immunodeficient recipients (NOG mice). To further elucidate the mechanisms of Atm-/-nu-/- tumor development we employed two types of genome wide analysis: spectral karyotype and RNAseq. This analysis revealed participation of three principal pathogenic mechanisms a) c-myc driven lymphomagenesis b) lymphomagenesis driven by translocations involving immune system genes and c) genomic instability as a major driving force associated with translocations involving chromosome 18 and multiple partners. In conclusion, by crossing Atm knockout mice with nude mice that have greatly diminished T cell development, we have generated a mouse model that faithfully recapitulates the range of Atm-deficient non Hodgkin's lymphomas observed in the general population as well as in A-T patients. Our model highlights the role of genomic instability in Atm-dependent lymphomagenesis, providing a powerful transplantable tool to study the principal pathways involved in Atm-deficient tumors and test their targetability by new compounds. Disclosures Griffiths: Affymetrix: Research Funding.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 446-446
Author(s):  
Mobin A. Karimi ◽  
Thai Cao ◽  
Michael R. Verneris ◽  
Jeanette Baker ◽  
Robert S. Negrin

Abstract NKG2D is a cell surface receptor expressed on NK cells, CD8+ T cells, γδ T cells and macrophages. NKG2D is activated by stress-induced ligands MICA and MICB, and UL16 binding proteins ULBP1, ULBP2 and ULBP3 which are expressed on target cells modified by infection, transformation or stress. Binding of NKG2D on NK cells results in an activation signal that bypasses or overrides inhibitory signals from major histocompatibility complex (MHC) class I specific receptors, resulting in cytotoxic granule content release and target cell killing. NKG2D on T cells co-stimulates effector T cell function. Signaling is achieved by selective expression of the adaptor proteins DAP10 and DAP12 which form distinct associations with NKG2D isoforms in different cell types. Previously we have shown that CD8+ T cells activated with INF-γ, anti CD3 MAB and IL2 express NKG2D and share functional and phenotypic properties with NK cells. Activated CD8+ T cells up-regulate NKG2D as well as DAP10 and DAP12 during ex-vivo activation and expansion which correlated with cytotoxic function. We demonstrated that CD8+ T cell-mediated cytotoxicity is MHC1 independent and that NKG2D monoclonal antibodies directed against NKG2D reduced cytotoxicity. To further elucidate the role of NKG2D signaling in CD8+ T cell-mediated cytotoxicity, six 21-nucleotide small interfering RNAs (siRNA) were designed against multiple sites within the NKG2D gene. The greatest suppression of NKG2D expression was observed with the siRNA targeting BP1546-1567 (siRNA #6) located between exon 8 and 9. FACS analysis, northern and western blots demonstrated that effecter cells transfected with siRNA #6 incorporated into the pLV ThM lentiviral vector resulted in >90% (P <.0001) suppression of NKG2D expression after 72 hrs. In both CD8+ T cells and NK cells, suppression of NKG2D resulted in a >90% decrease in cytotoxicity against multiple myeloma tumor cell line targets (RPMI and U266). We also performed experiments using cells derived from the peripheral blood of ovarian cancer patients and autologous tumor targets derived from ascites. Similar to the results obtained using CD8+ T cells and NK cells against multiple myeloma cell lines, suppressing NKG2D expression in activated CD8+ T Cells resulted in >90% decrease in cytotoxicity against the autologous tumor targets. To characterize the role of DAP10 and DAP12 adaptor molecules in NKG2D cytotoxic signaling, we generated three siRNA molecules spanning DAP10 and four siRNA molecules for DAP12. Using northern blot analysis, >90% suppression of DAP 10 was observed when CD8+ T cells and NK cells were treated with the siRNA targeting BP356-377. A similar level of silencing of DAP12 was observed using a siRNA targeting BP 323-344 of DAP 12. Suppression of DAP10 expression in CD8+ T cells and NK cells resulted in a decrease in cytotoxicity of more than ~75% (P .0003) compared to untreated cells or cells treated with a control siRNA, siRNA against murine CD8. Suppressing DAP12 expression also resulted in significant reduction in cytoxicity, however was consistently less than that of DAP10. When DAP10 and DAP12 ware simultaneously silenced in CD8+ T and NK cells, an ~82% (P <.0001) reduction in cytotoxicity was observed. While DAP 10 is known to play a key role in NKG2D signaling, other adaptor proteins such as DAP12, also are involved in activated and expanded CD8+ T cell cytotoxicity.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 3805-3805
Author(s):  
Joanne E Davis ◽  
Michael Harvey ◽  
Nicholas A Gherardin ◽  
Rachel Koldej ◽  
Nicholas Huntington ◽  
...  

Abstract Introduction Immunosuppressive pre-transplantation conditioning is essential for donor cell engraftment in allogeneic bone marrow transplant (BMT). The role of residual post-conditioning recipient immunity in determining engraftment is poorly understood. Although recipient perforin has previously been shown to modulate myeloid engraftment from mouse bone marrow, and adoptive transfer of natural killer (NK) cells can ameliorate the onset of graft-versus host disease (GVHD), the role of perforin-expressing endogenous recipient NK and NKT cells in modulating donor T cell engraftment has not been described. Using an MHC-mismatched mouse model, we examined the role of perforin-expressing NK cells in regulating both the rate and activation status of donor lymphocyte engraftment after allogeneic transplantation. Methods An MHC-disparate model of BMT was established transplanting BALB/c donor BM (H-2Kd), into female 6-14 week old C57BL/6 WT and C57BL/6.perforin KO (H-2Kb) recipients. On day 0, recipient mice were administered a split dose of lethal radiation using a caesium source (2 x 6 gray), and injected i.v. with 5e6 T cell depleted BM (TCD-BM) cells from MHC-mismatched or syngeneic donors. On day 2, recipient mice were injected i.v. with 1e6 BALB/c purified splenic T cells at a 2:1 CD4+:CD8+ T cell ratio. Mice were monitored daily, and killed at selected time points post-transplant (typically day 5-7 for short term engraftment, or day 20 for long term engraftment) to examine donor lymphoid cell engraftment. Results An HLA-mismatched BMT mouse model demonstrated that both the rate and proportion of donor lymphoid cell engraftment, and expansion of effector memory donor T cells in both spleen and BM were significantly increased within 5-7 days post BMT in perforin-deficient (pfn-/-) recipients, compared with wild-type (WT). Critically, we found that the absence of perforin resulted in the increased production of pro-inflammatory cytokines, in particular IL-6, from engrafting donor T cells. IL-6 has recently been identified as a primary driver of both mouse model and clinical GVHD. Correlating with pro-inflammatory cytokine secretion, effector memory donor T lymphocytes expanded more rapidly in pfn-/- recipients than in WT mice, possibly arising from more rapid proliferation or selective survival of these donor cells. In WT recipients, donor lymphoid cell engraftment was enhanced to that seen in pfn-/- recipients, by depleting NK cells prior to BMT, demonstrating that a perforin-dependent, NK-mediated host-versus graft effect limits the rate of donor cell engraftment and T cell activation. We found that radiation-resistant NKT cells survived in the BM of lethally irradiated mice and may drive NK cell activation, resulting in the host-versus graft effect. Furthermore, reduced pre-transplant irradiation doses in pfn-/- recipients permitted long-term donor lymphoid cell engraftment and improved survival (Figure 1). Figure 1: Reduced total body irradiation in perforin-deficient mice permits rapid donor lymphoid cell engraftment. On day 0, WT or pfn-/- (KO) mice were irradiated with variable doses (12-6 gray), and injected i.v. with 5e6 TCD-BM cells from BALB/c donors. On day 2, recipient mice were injected i.v. with 1e6 splenic BALB/c T cells. On day 7 (A) and day 20 (B) after BMT, the BM cells of WT or KO mice were stained for H-2Kd (donor cells) and engraftment determined as a percentage of donor lymphocytes. (C) Survival of KO mice administered 9 gray (closed circles), 7.5 gray (triangles) and 6 gray (lines) after BMT described above. Figure 1 Figure 1. Figure 2 Figure 2. Figure 3 Figure 3. Conclusions The challenge in clinical HSCT is to promote reliable donor engraftment and full immunological reconstitution whilst minimizing pre-transplant conditioning and associated toxicity. Our findings suggest that suppression of perforin activity or selective depletion of recipient NK cells prior to BMT may allow the combined advantage of reduced transplant toxicity whilst maintaining donor engraftment and promoting the graft versus tumour effect. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document